当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

Abstract：

:Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prognostic value of matrix metalloproteinase-2 (MMP-2) and age was evaluated in 108 premenopausal, node-positive breast carcinoma patients treated with an adjuvant chemotherapy. Expression of MMP-2 protein was studied in paraffin-embedded tissue sections from primary tumors by using specific MMP-2 monoclonal antibody in an immunohistochemical staining. Age less than 40 years predicted 5-year recurrence free survival (RFS) as unfavorable, being 74% in patients 41-49 years of age and 54% in those under age 40 (p = 0.02). The 5-year RFS rate was 85% in patients with an MMP-2 negative primary tumor while it was 65% in the MMP-2 positive patient group. This difference was not, however, statistically significant (p = 0.07). Correlation between hematogenous metastasis and MMP-2 positivity in breast carcinoma was demonstrated for the first time (p = 0.03). A risk group for a relapse was identified using MMP-2 immunohistochemistry and age. The RFS rate in patients less than 40 years with an MMP-2 positive primary tumor was only 50% while it was 74% in other premenopausal patients (p = 0.007). Young age and MMP-2 positivity may, thus, associate with early relapse in node-positive breast carcinoma.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

doi

10.1023/a:1006326513176

subject

Has Abstract

pub_date

1999-12-01 00:00:00

pages

287-93

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

58

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.

    abstract：PURPOSE:The RAS family comprises three proto-oncogenes (H-RAS, K-RAS, and N-RAS) and is among the most widely studied of oncogenes. The present study aimed at investigating the clinical relevance of mRNA levels of the three isoforms in a large group of breast cancer patients with a long-term follow-up. METHODS:198 pre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05474-8

    authors： Banys-Paluchowski M,Milde-Langosch K,Fehm T,Witzel I,Oliveira-Ferrer L,Schmalfeldt B,Müller V

    更新日期：2020-01-01 00:00:00

  • Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors.

    abstract：:In breast cancer, the survival rate strongly depends on the number of lymph nodes involved. A drug with a specific inhibitory activity on lymph node and organ metastases would therefore be a candidate for adjuvant therapy after surgery. Prostacyclin and its stable analogues have been shown to interfere with certain st...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803791

    authors： Schneider MR,Schirner M,Lichtner RB,Graf H

    更新日期：1996-01-01 00:00:00

  • Breast cancer prevention through modulation of endogenous hormones.

    abstract：:The use of exogenous sex-steroids for hormonal contraception is important to the way of life of many modern women. The widespread use of hormonal contraceptives represents a unique opportunity to have a substantial positive impact on women's health. The observation that users of oral combination type contraceptives ha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666430

    authors： Spicer DV,Pike MC

    更新日期：1993-11-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract：:The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0080-8

    authors： Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期：2009-05-01 00:00:00

  • Inflammatory breast cancer (IBC): clues for targeted therapies.

    abstract：:Inflammatory breast cancer (IBC) is the most aggressive type of advanced breast cancer characterized by rapid proliferation, early metastatic development and poor prognosis. Since there are few preclinical models of IBC, there is a general lack of understanding of the complexity of the disease. Recently, we have devel...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2600-4

    authors： Fernandez SV,Robertson FM,Pei J,Aburto-Chumpitaz L,Mu Z,Chu K,Alpaugh RK,Huang Y,Cao Y,Ye Z,Cai KQ,Boley KM,Klein-Szanto AJ,Devarajan K,Addya S,Cristofanilli M

    更新日期：2013-07-01 00:00:00

  • Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors.

    abstract：:The epidermal growth factor system is a well characterized growth factor receptor pathway, the deregulation of which has been be associated with neoplastic growth. Overexpression or amplification of the epidermal growth factor receptor (EGFR) or one of its ligands has been linked with the malignant transformation of c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000010702.10130.29

    authors： Rae JM,Lippman ME

    更新日期：2004-01-01 00:00:00

  • Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

    abstract：:Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot co...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s10549-011-1612-1

    authors： Hadad S,Iwamoto T,Jordan L,Purdie C,Bray S,Baker L,Jellema G,Deharo S,Hardie DG,Pusztai L,Moulder-Thompson S,Dewar JA,Thompson AM

    更新日期：2011-08-01 00:00:00

  • Flexible covariate effects in the proportional hazards model.

    abstract：:The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01840837

    authors： Hastie T,Sleeper L,Tibshirani R

    更新日期：1992-01-01 00:00:00

  • GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.

    abstract：:We investigated the role of glial cell line-derived neurotrophic factor (GDNF) in compensating trastuzumab (TZMB)-induced apoptosis in HER2+ breast cancer (BC) cells using xenograft tumors. We generated BC xenografts in nude mice using samples from three patients selected based on their HER2 status and response to TZM...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4078-3

    authors： Gardaneh M,Shojaei S,Kaviani A,Behnam B

    更新日期：2017-04-01 00:00:00

  • Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage.

    abstract：:The biological and clinical significance of circulating tumor cells (CTC) in the peripheral blood of breast cancer patients is not known. To study this question, we used a direct visualization assay to correlate the number of CTC with disease stage and progression. The CTC were enriched from the nucleated cell fractio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000036897.92513.72

    authors： Kahn HJ,Presta A,Yang LY,Blondal J,Trudeau M,Lickley L,Holloway C,McCready DR,Maclean D,Marks A

    更新日期：2004-08-01 00:00:00

  • Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo.

    abstract：:The glycolytic phenotype is a widespread phenomenon in solid cancer forms, including breast cancer. Dichloroacetate (DCA) has recently been proposed as a novel and relatively non-toxic anti-cancer agent that can reverse the glycolytic phenotype in cancer cells through the inhibition of pyruvate dehydrogenase kinase. W...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0435-9

    authors： Sun RC,Fadia M,Dahlstrom JE,Parish CR,Board PG,Blackburn AC

    更新日期：2010-02-01 00:00:00

  • Association of a TGF-β1 gene -509 C/T polymorphism with breast cancer risk: a meta-analysis.

    abstract：:Transforming growth factor-β1 (TGF-β1) is negative regulator of cell proliferation and the cell cycle, and plasma levels of TGF-β1 are twice as high in TGF-β1 -509 T homozygotes as in -509 C homozygotes. Published studies on the association between the TGF-β1 gene -509 C/T polymorphism and breast cancer risk are incon...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-010-0871-6

    authors： Woo SU,Park KH,Woo OH,Yang DS,Kim AR,Lee ES,Lee JB,Kim YH,Kim JS,Seo JH

    更新日期：2010-11-01 00:00:00

  • Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study.

    abstract：:Seroma formation after axillary lymphadenectomy in women with breast cancer remains a problem despite many efforts to reduce surgery-related morbidity. In a prospective, randomised, open, parallel-group, controlled clinical trial we evaluated the effect of a fibrin-glue coated collagen patch (TachoComb H, Nycomed Phar...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1010671209279

    authors： Berger A,Tempfer C,Hartmann B,Kornprat P,Rossmann A,Neuwirth G,Tulusan A,Kubista E

    更新日期：2001-05-01 00:00:00

  • Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

    abstract：BACKGROUND:The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. PATIENTS AND METHODS:In all, 541 pati...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05746-8

    authors： Walter V,Fischer C,Deutsch TM,Ersing C,Nees J,Schütz F,Fremd C,Grischke EM,Sinn P,Brucker SY,Schneeweiss A,Hartkopf AD,Wallwiener M

    更新日期：2020-08-01 00:00:00

  • Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.

    abstract：PURPOSE:To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS:A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-u...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4491-2

    authors： Siegelmann-Danieli N,Katzir I,Landes JV,Segal Y,Bachar R,Rabinovich HR,Bialik M,Azuri J,Porath A,Lomnicky Y

    更新日期：2018-01-01 00:00:00

  • Mutation analysis of PALB2 gene in French breast cancer families.

    abstract：:Several population-based and family-based studies have demonstrated that germline mutations of the PALB2 gene (Partner and Localizer of BRCA2) are associated with an increased risk of breast cancer. Distinct mutation frequencies and spectrums have been described depending on the population studied. Here we describe th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3625-7

    authors： Damiola F,Schultz I,Barjhoux L,Sornin V,Dondon MG,Eon-Marchais S,Marcou M,GENESIS Study Investigators.,Caron O,Gauthier-Villars M,de Pauw A,Luporsi E,Berthet P,Delnatte C,Bonadona V,Maugard C,Pujol P,Lasset C,Longy M

    更新日期：2015-12-01 00:00:00

  • Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer.

    abstract：PURPOSE:To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician. PATIENTS AND METHODS:Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized pha...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1023/a:1006483214678

    authors： Okamura H,Yamamoto N,Watanabe T,Katsumata N,Takashima S,Adachi I,Kugaya A,Akechi T,Uchitomi Y

    更新日期：2000-05-01 00:00:00

  • A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.

    abstract：PURPOSE:This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer. PATIENTS AND METHODS:The study enrolled 155 women with pathologically confirmed and measurable metastatic adenocarcinoma of t...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1021384318470

    authors： Loesch DM,Asmar L,Canfield VA,Parker GA,Hynes HE,Ellis PG,Ferri WA Jr,Robert NJ

    更新日期：2003-01-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract：:The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803781

    authors： Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期：1996-01-01 00:00:00

  • Breast sarcomas and malignant phyllodes tumours: comparison of clinicopathological features, treatment strategies, prognostic factors and outcomes.

    abstract：:We aimed to compare the clinicopathological features, treatment strategies and clinical outcomes of breast sarcomas (BS) and malignant phyllodes tumours (MPT), and determine their prognostic factors. Cases of BS and MPT diagnosed at the Department of Pathology, Singapore General Hospital from January 1991 to December ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3946-1

    authors： Lim SZ,Selvarajan S,Thike AA,Nasir ND,Tan BK,Ong KW,Tan PH

    更新日期：2016-09-01 00:00:00

  • Impact of real-time virtual sonography, a coordinated sonography and MRI system that uses an image fusion technique, on the sonographic evaluation of MRI-detected lesions of the breast in second-look sonography.

    abstract：:The aim of this study was to verify the utility of second-look sonography using real-time virtual sonography (RVS)-a coordinated sonography with an MRI system that uses an image fusion technique with magnetic navigation-on the sonographic evaluation of MRI-detected lesions of the breast. Of the 196 consecutive patient...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2163-9

    authors： Nakano S,Kousaka J,Fujii K,Yorozuya K,Yoshida M,Mouri Y,Akizuki M,Tetsuka R,Ando T,Fukutomi T,Oshima Y,Kimura J,Ishiguchi T,Arai O

    更新日期：2012-08-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract：:Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-010-0827-x

    authors： Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期：2010-06-01 00:00:00

  • Sexual health in long-term breast cancer survivors.

    abstract：PURPOSE:Sexual dysfunction is reported in women with breast cancer (BC). It is unclear whether symptoms persist over time as data comparing long-term survivors to controls are lacking. We compared sexual functioning in long-term breast cancer survivors (BCS) to controls and determined the impact of adjuvant therapy on ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4894-8

    authors： Soldera SV,Ennis M,Lohmann AE,Goodwin PJ

    更新日期：2018-11-01 00:00:00

  • Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.

    abstract：:Aberrant expressions of the neuronal protein synuclein gamma (SNCG) in malignant mammary epithelial cells are strongly associated with the progression of breast cancer. SNCG is not expressed in normal breast tissues but abundantly expressed in a high percentage of invasive and metastatic breast carcinomas. Several stu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-6938-0

    authors： Inaba S,Li C,Shi YE,Song DQ,Jiang JD,Liu J

    更新日期：2005-11-01 00:00:00

  • Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.

    abstract：:The spectrum of germline mutations among Jewish non Ashkenazi high risk breast/ovarian cancer families includes a few predominant mutations in BRCA1 (185delAG and Tyr978X) and BRCA2 (8765delAG). A few additional recurring mutations [A1708E, 981delAT, C61G (BRCA1) R2336P, and IVS2 + 1G > A (BRCA2)] have been reported i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2006-8

    authors： Laitman Y,Simeonov M,Herskovitz L,Kushnir A,Shimon-Paluch S,Kaufman B,Zidan J,Friedman E

    更新日期：2012-06-01 00:00:00

  • Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

    abstract：:We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but n...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806133

    authors： Gill PG,Vignon F,Bardon S,Derocq D,Rochefort H

    更新日期：1987-10-01 00:00:00

  • Central nervous system metastases in women after multimodality therapy for high risk breast cancer.

    abstract：BACKGROUND:Central nervous system (CNS) relapse is increasing in breast cancer. This increase may reflect altered failure patterns from adjuvant therapy, more effective systemic therapy with improved control in non-CNS sites, or a resistant breast cancer subtype. METHODS:To determine the factors associated with clinic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-0999-3

    authors： Carey LA,Ewend MG,Metzger R,Sawyer L,Dees EC,Sartor CI,Moore DT,Graham ML

    更新日期：2004-12-01 00:00:00

  • A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

    abstract：:The goal of this study was to compare the efficacy and toxicity of chemotherapy to exemestane plus everolimus (EXE/EVE) through a network meta-analysis (NMA) of randomized controlled trials. NMA methods extend standard pairwise meta-analysis to allow simultaneous comparison of multiple treatments while maintaining ran...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-015-3453-9

    authors： Generali D,Venturini S,Rognoni C,Ciani O,Pusztai L,Loi S,Jerusalem G,Bottini A,Tarricone R

    更新日期：2015-07-01 00:00:00

  • Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior.

    abstract：BACKGROUND:Epithelial-to-mesenchymal transition (EMT) has been implicated as an important step in the development of distant metastases. We therefore wished to study EMT status of primary breast carcinomas from patients who during follow-up developed distant metastases. METHODS:mRNA expression profiles of primary brea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05089-5

    authors： Savci-Heijink CD,Halfwerk H,Hooijer GKJ,Koster J,Horlings HM,Meijer SL,van de Vijver MJ

    更新日期：2019-04-01 00:00:00

  • A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.

    abstract：:While it has been demonstrated that prophylactic mastectomy reduces breast cancer incidence among women at high risk, many women often consider this disfiguring surgery unacceptable. One alternative approach may be breast reduction surgery. In order to evaluate the long-term incidence of breast cancer following surgic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9099-2

    authors： Fryzek JP,Ye W,Nyrén O,Tarone RE,Lipworth L,McLaughlin JK

    更新日期：2006-05-01 00:00:00